



EDITOR

Jeffrey D. Bernhard, MD

Journal of the American Academy of Dermatology
University of Massachusetts Medical School
55 Lake Avenue North
Worcester, MA 01655
Phone: 508-856-2583; fax: 508-856-5687
E-mail: melissa.derby@umassmed.edu

PUBLISHER

Elsevier Inc.

11830 Westline Industrial Dr.
St. Louis, MO 63146-3318

Susan M. Kell, Senior Issue Manager

Phone: 215-239-3380; fax: 215-239-3388
E-mail: s.kell@elsevier.com

INFORMATION FOR AUTHORS

All manuscripts must be submitted via Editorial Manager™ (<http://jaad.editorialmanager.com>).

The Information for Authors undergoes continuous revision. The most current version can be found at www.eblue.org. All manuscripts for the Journal of the American Academy of Dermatology must be submitted electronically through the Web-based Editorial Manager™ program. Editorial Manager™ may be accessed by visiting <http://jaad.editorialmanager.com>. The site provides instructions for manuscript submission as well as a tutorial for authors. Word, WordPerfect, RTF, and Text files will be accepted; Word and WordPerfect are preferred. All tracking and follow-up will be done through Editorial Manager™ (<http://jaad.editorialmanager.com>). Questions about the program may be addressed to melissa.derby@umassmed.edu. All manuscript submissions must include the copyright transfer form, the conflict of interest disclosure form, the authorship statement (attestation) form, and the manuscript submission checklist. These forms can be copied from the January or July issues of the Journal and/or downloaded from either our Web site (<http://www.eblue.org>) or Editorial Manager™ (<http://jaad.editorialmanager.com>).

Editorial policies. The Journal of the American Academy of Dermatology is a refereed journal designed to meet the continuing education needs of the Academy members and the international dermatologic community. The Journal bases its policies on the guidelines set forth by the International Committee of Medical Journal Editors (<http://www.icmje.org>).

Disclaimer. Statements and opinions expressed in the articles and communications herein are those of the author(s) and not necessarily those of the Editor(s), publisher, or Academy. The Editor(s), publisher, and Academy disclaim any responsibility or liability for such material and do not guarantee, warrant, or endorse any product or service advertised in this publication. Neither do they guarantee any claim made by the manufacturer of such product or service.

Conflict of interest. The Journal requires all authors to acknowledge, in the comments section of Editorial Manager™ (<http://jaad.editorialmanager.com>), all funding sources that supported their work as well as all institutional or corporate affiliations of the authors. **The title page must also include a publishable statement disclosing any commercial associations, current and over the past 5 years, that might pose a conflict of interest.** These include but are not limited to consultant arrangements, stock or other equity ownership, stock options, patent

licensing arrangements, payments for conducting or publicizing the study, and consulting relationships with investment companies. In addition, authors are required to disclose similar associations with companies that make a competing product. When no competing interests are present, the publishable disclosure statement should say so. If the authors have competing or conflicting interests that cannot be disclosed in publishable statements, please list them in the comments section of Editorial Manager™ (<http://jaad.editorialmanager.com>). They should also explain these as well as the reason for needing confidentiality in a statement to the Editor. The Editor asks each reviewer to disclose any competing interests (or to recuse oneself if a competing interest might interfere with one's objectivity). The Editors and members of the editorial staff have registered their competing interests, if any, with the officers of the American Academy of Dermatology. An authorship statement and conflict of interest statement must be submitted. Both forms are included in the January and July issues of the Journal (see last page of Contents for page number) and are available for download from the Editorial Manager™ Web site (<http://jaad.editorialmanager.com>).

Authorship. The journal's authorship criteria are adapted from those of the International Committee of Medical Journal Editors and are delineated on the Authorship Statement, which must be signed by each author.

Role of writers, "ghost writers," and other "third parties" involved in manuscript development and production. The involvement, nature of involvement, and affiliation or support of any medical writers, "ghost writers," or other individuals or companies or third parties involved in the development or writing of all papers must be noted and explained in the cover letter and in a publishable statement on the manuscript title page. (This does not include things like typing or photocopying.) These will be published as part of the first-page footnotes. All individuals involved in the preparation and writing of each paper who meet the JAAD's authorship criteria (see our Authorship Statement) must be listed as authors. The names, highest academic degree, and affiliations of any persons who contributed to writing the paper or analyzing the data who do not meet authorship criteria must be included in the paper's Acknowledgements along with a disclosure of any pertinent conflicts of interest. Individuals listed in the Acknowledgement because of such contributions to the work should provide written consent.

Special requirements for studies involving live human or animal subjects. Studies involving live human or animal subjects must have been approved by the authors'

Institutional Review Board or its equivalent. A copy of the IRB approval letter must be included with your submission or sent to the Journal office under separate cover. If applicable, IRB approval must be mentioned in the methods section of all manuscripts. Do not identify patients by name or initials; numbers should be used. No other information, including clinical photos or family trees, from which a patient could be identified is permitted unless express written permission from the patient/family is provided at the time of manuscript submission. All clinical investigations must have been conducted according to the Declaration of Helsinki principles. If the methods section is not sufficiently clear, authors may be asked to provide the editors with a copy of IRB-approved research protocols for the use of our reviewers.

Special requirements for submission of survey research. Submissions of survey research must include: 1. A copy of the letter documenting Human Subject Institutional Review Board (IRB) approval. 2. A copy of the survey instrument. (The editors, in consultation with the authors, will determine if the survey instrument should be published and whether it should be published as an online only appendix.) The manuscript's methods section must: 1. Attest that the use of any proprietary sampling contact information (e.g. mailing list) was approved by its owner. 2. Provide IRB protocol approval number and date. 3. Describe how the survey instrument was developed and piloted, and whether/how the survey was validated. During the review process, editors and reviewers may request a copy of the approved study protocol to aid in their evaluation of the study.

Randomized trials. Randomized trials must be submitted in a format consistent with the CONSORT statement, along with a completed CONSORT manuscript submission checklist. The word "random" or "randomized" should be in the title. The updated CONSORT guidelines can be accessed by visiting <http://www.consort-statement.org>. To obtain a copy of the "CONSORT Checklist for Authors Submitting Reports of Randomized Controlled Trials" you may download it from the Editorial Manager™ Web site (<http://jaad.editorialmanager.com>).

Priority claims, "firstedness." Please do not claim that your report is the first reported case. If you feel that you must do so, please explain why in your cover letter and please provide a detailed Appendix on how you came to this conclusion. Describe your search strategies, search terms, databases queried, and how far back you checked. Also list textbooks and monographs that were searched to substantiate your claim.

Trade names. Trade names and brand names of drugs and devices may not be used in the title of the paper. They may appear only once in the paper and should follow the generic name in parenthesis; this use should preferably be in the abstract or in a table of brand names and generic names, if that is a more reasonable way to proceed. Thereafter, only generic names should be used throughout the article.

On brevity and other matters of style. Brevity is appreciated. Authors should avoid repeating the same information in the abstract, introduction, and discussion.

Copyright transfer. In accordance with the Copyright Act of 1976, which became effective January 1, 1978, the following statement signed by *each* author must ac-

company the manuscript submitted: "I, the undersigned author, transfer all copyright ownership of the manuscript referenced above to the American Academy of Dermatology, in the event the work is published. I warrant that the article is original, does not infringe upon any copyright or other proprietary right of any third party, is not under consideration by another journal, and has not been published previously. I have reviewed and approve the submitted version of the manuscript and agree to its publication in the Journal of the American Academy of Dermatology." A copyright transfer form is included in the January and July issues of the Journal (see last page of Contents for page number) and may be downloaded from the Editorial Manager™ Web site (<http://jaad.editorialmanager.com>). Author(s) will be consulted, whenever possible, regarding republication of material.

US National Institutes of Health (NIH) voluntary posting/ "Public Access Policy": Elsevier facilitates author posting in connection with the voluntary posting request of the NIH (referred to as the NIH "Public Access Policy", see <http://www.nih.gov/about/publicaccess/index.htm>) by posting the peer-reviewed author's manuscript directly to PubMed Central on request from the author, 12 months after formal publication. Upon notification from the Editorial Office of acceptance, we will ask you to confirm via e-mail (by e-mailing us at NIHauthorrequest@elsevier.com) that your work has received NIH funding (with the NIH award number) and that you intend to respond to the NIH request. Upon such confirmation, Elsevier will submit to PubMed Central on your behalf a version of your manuscript that includes all changes made during the review and proofing process, for posting 12 months after the formal publication date. This will ensure that you will have responded fully to the NIH request policy. There will be no need for you to post your manuscript directly to PubMed Central, and any such posting is prohibited. Individual modifications to this general policy may apply to some Elsevier journals and its society publishing partners.

Sections/article type guidelines

Continuing Medical Education: In-depth, substantiated, educational articles presenting core information for the continuing medical education of the practicing dermatologist. In order to avoid duplication, authors may wish to contact the managing editor (melissa.derby@umassmed.edu) early on in the development of the article. Please provide 3 learning objectives for your article. Learning objectives should convey what the participant will be able to do after completing the CME activity. The learning objectives should be measurable and written in active learning terms. The following verbs are suggestions for your consideration in writing your objectives: analyze, apply, assess, categorize, choose, compare, complete, define, demonstrate, describe, design, detect, determine, develop, diagnose, differentiate, discuss, distinguish, draw, evaluate, examine, formulate, identify, list, locate, manage, measure, name, order, outline, predict, prepare, prescribe, recognize, select, summarize, test, treat, use, and utilize. Learning objectives should be listed in the following format: Following this activity, the participant will be able to: 1. _____; 2. _____; and 3. _____. (Eg, Following the activity, the participant will be able to: 1. diagnose skin diseases more effectively; 2. order appropriate

Download English Version:

<https://daneshyari.com/en/article/3211803>

Download Persian Version:

<https://daneshyari.com/article/3211803>

[Daneshyari.com](https://daneshyari.com)